Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Combining targeted therapies significantly boosted survival in kidney cancer study (opens in a new tab)

medicalxpress.com · 2026-10-28

Short answerEvidenceSource

Short answer

Not supported

Not supported.

2 claims go further than the study. 3 other points were not covered by the paper.

  • 2 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

Two of five claims overstate the study. Three claims the study doesn't address.

  • 2 overstated
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedA phase 1/2 trial led by Roswell Park Comprehensive Cancer Center found that combining bevacizumab and pazopanib significantly extends progression-free and overall survival in patients with the most common type of kidney cancer.View evidenceHide evidence

Why this verdict

The abstract profile supports that this was a multicentre single-arm phase 2 evaluation in treatment-naive metastatic clear-cell RCC and that median PFS was 24.8 months. It does not support the headline's unhedged causal wording that the regimen 'significantly extends' survival, because there was no randomized comparator in the abstract-level evidence. The supplied abstract profile also does not verify an overall-survival result. The headline therefore outruns what the single-arm body evidence can establish.

1

Study evidence

In the phase 2 cohort (treatment‑naive metastatic clear‑cell RCC), median progression‑free survival was 24.8 months (95% CI 17.2–34.3) after a median follow‑up of 63.7 months.median PFS 24.8 months (95% CI 17.2–34.3)

“The phase 2 portion enrolled only patients with treatment-naive metastatic clear-cell renal cell carcinoma.”
Claim 2 of 5OverstatedThe article says the regimen was safe and efficacious, reasonably well tolerated, and delayed development of treatment resistance; high blood pressure and elevated liver enzymes were the most common serious side effects.View evidenceHide evidence

Why this verdict

The abstract profile supports that the regimen showed promising antitumour activity and that the most common grade 3–4 treatment-related adverse events were hypertension and elevated AST/ALT. But the unhedged claim that the regimen was 'safe and efficacious' and delayed treatment resistance overstates single-arm phase 1/2 evidence. The abstract profile does not directly establish delayed development of resistance, and it reports grade 3–4 treatment-related adverse events rather than specifically identifying hypertension and liver-enzyme elevations as the most common serious adverse events.

1

Study evidence

In the phase 2 cohort (treatment‑naive metastatic clear‑cell RCC), median progression‑free survival was 24.8 months (95% CI 17.2–34.3) after a median follow‑up of 63.7 months.median PFS 24.8 months (95% CI 17.2–34.3)

“The phase 2 portion enrolled only patients with treatment-naive metastatic clear-cell renal cell carcinoma.”
2

Study evidence

Grade 3–4 treatment-related adverse events were reported in the pooled safety population; the most common were hypertension, elevated alanine aminotransferase (ALT), and elevated aspartate aminotransferase (AST).Hypertension 20/59 (34%); ALT elevation 10/59 (17%); AST elevation 7/59 (12%)

“Safety analyses included all patients who received any treatment.”
Claim 3 of 5Not coveredThe trial was a nationwide, multicenter study of 51 patients, and the strongest benefit was seen in favorable-risk patients.View evidenceHide evidence

As stated51 patients

Why this verdict

The abstract profile supports a multicentre study and 51 patients evaluable for phase 2 activity, but it describes five US academic cancer centres rather than verifying the story's 'nationwide' framing. The assertion that the strongest benefit was seen in favorable-risk patients is not established in the supplied abstract profile; the profile only notes that the phase 2 population was predominantly favourable-risk, not subgroup benefit estimates.

1

Study evidence

In the phase 2 cohort (treatment‑naive metastatic clear‑cell RCC), median progression‑free survival was 24.8 months (95% CI 17.2–34.3) after a median follow‑up of 63.7 months.median PFS 24.8 months (95% CI 17.2–34.3)

“The phase 2 portion enrolled only patients with treatment-naive metastatic clear-cell renal cell carcinoma.”
Claim 4 of 5Not coveredIn the phase 2 portion, the 51 treated patients had median progression-free survival of 24.8 months and median overall survival of 63.2 months after a median follow-up of 63.7 months.View evidenceHide evidence

As stated24.8 months PFS; 63.2 months OS; 63.7 months follow-up

Why this verdict

The abstract profile supports median follow-up of 63.7 months and median PFS of 24.8 months in the phase 2 activity-evaluable population. However, it reports 51 patients as evaluable for activity, not simply '51 treated patients,' and the supplied abstract profile does not verify the stated median overall survival of 63.2 months.

1

Study evidence

In the phase 2 cohort (treatment‑naive metastatic clear‑cell RCC), median progression‑free survival was 24.8 months (95% CI 17.2–34.3) after a median follow‑up of 63.7 months.median PFS 24.8 months (95% CI 17.2–34.3)

“The phase 2 portion enrolled only patients with treatment-naive metastatic clear-cell renal cell carcinoma.”
Claim 5 of 5Not coveredAmong the 33 favorable-risk patients, the article says progression-free survival was 28.5 months and overall survival was 76.9 months.View evidenceHide evidence

As stated33 patients; 28.5 months PFS; 76.9 months OS

Why this verdict

The abstract profile indicates that the phase 2 population was predominantly favourable-risk, which is consistent with approximately 33 favourable-risk patients, but it does not provide favourable-risk subgroup PFS or OS estimates. The stated 28.5-month PFS and 76.9-month OS for favourable-risk patients therefore cannot be verified at abstract depth.

1

Study evidence

In the phase 2 cohort (treatment‑naive metastatic clear‑cell RCC), median progression‑free survival was 24.8 months (95% CI 17.2–34.3) after a median follow‑up of 63.7 months.median PFS 24.8 months (95% CI 17.2–34.3)

“The phase 2 portion enrolled only patients with treatment-naive metastatic clear-cell renal cell carcinoma.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The activity analysis was per-protocol after completion of one full 10-week cycle, which can select for patients who tolerated or completed initial therapy.

    This limitation is material to interpreting the 51-patient activity results, but it is not included in the story caveats.

    From single-arm phase 2 interventional oncology trial

  • The phase 2 population was predominantly favourable-risk and predominantly White, limiting generalizability to other risk groups and populations.

    The story notes that benefit was strongest in favourable-risk patients, but the supplied abstract profile does not verify that subgroup-benefit claim and the story caveats do not acknowledge the population-skew/generalizability limitation.

    From single-arm phase 2 interventional oncology trial; Pooled safety analysis (all treated patients across phase 1 and phase

4 things the story did carry across
  • Phase 1 dose-finding established the recommended phase 2 dose of pazopanib 800 mg daily on days 1–28 plus bevacizumab 10 mg/kg on days 36 and 50 of a 10-week cycle.
  • Phase 2 was a multicentre single-arm activity evaluation in treatment-naive metastatic clear-cell RCC, with median PFS as the primary endpoint assessed by masked central statistician review.
  • The phase 2 activity result was median PFS 24.8 months after median follow-up 63.7 months in 51 activity-evaluable patients, not necessarily all treated/enrolled phase 2 patients.
  • Pooled safety analysis in 59 treated patients found common grade 3–4 treatment-related adverse events of hypertension, ALT elevation, and AST elevation; five patients discontinued for drug-related serious adverse events and no treatment-related deaths occurred.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEstimate antitumour activity of the alternating pazopanib–bevacizumab regimen in treatment-naive metastatic clear-cell renal cell carcinoma, primarily via centrally assessed progression-free survival (phase 2).single-arm phase 2 interventional oncology trialExpand

In plain English

Single-arm, multicentre phase 2 evaluation of an alternating pazopanib (TKI) and bevacizumab regimen in treatment‑naive metastatic clear‑cell renal cell carcinoma, with primary efficacy endpoint median progression‑free survival (PFS) assessed by a masked central statistician review. Phase 2 enrolled 53 patients (51 evaluable for activity, including six carried from phase 1); after median follow‑up 63.7 months median PFS was 24.8 months (95% CI 17.2–34.3).

Key findings

  • In the phase 2 cohort (treatment‑naive metastatic clear‑cell RCC), median progression‑free survival was 24.8 months (95% CI 17.2–34.3) after a median follow‑up of 63.7 months.median PFS 24.8 months (95% CI 17.2–34.3)
“The phase 2 portion enrolled only patients with treatment-naive metastatic clear-cell renal cell carcinoma.”
What this piece can’t prove
  • Single‑arm phase 2 study without randomized comparator (reported in abstract).
  • Per‑protocol activity analysis (after one full 10‑week cycle) may select for patients who tolerate/complete initial treatment cycles.
  • Phase 2 activity evaluable set included six patients from phase 1 (as reported), potentially affecting the strictly 'phase 2 only' population definition.

1 further detail could not be confirmed from the summary.

2human in vivoEstablish the recommended phase 2 dose (RP2D) and characterize dose-limiting toxicity/safety of an alternating pazopanib–bevacizumab regimen in metastatic clear-cell renal cell carcinoma (phase 1).Phase 1 dose-escalation/selectionExpand

In plain English

Phase 1 dose-escalation portion of a multicentre single-arm trial tested four planned dose combinations of pazopanib (600 or 800 mg daily, days 1–28, followed by 7-day break) alternating with bevacizumab (5, 7.5, or 10 mg/kg given on days 36 and 50) on a 10-week cycle to identify a recommended phase 2 dose (RP2D) using an extended 15-week dose-limiting toxicity (DLT) assessment window. 25 patients were enrolled in phase 1, 18 were evaluable for DLTs during the extended 15-week safety assessment, and the RP2D was established as pazopanib 800 mg daily (days 1–28) with bevacizumab 10 mg/kg on days 36 and 50 of a 10-week cycle.

Key findings

  • The phase 1 portion established the RP2D for the alternating pazopanib–bevacizumab regimen.
  • Dose selection concluded with pazopanib 800 mg daily (days 1–28) plus bevacizumab 10 mg/kg on days 36 and 50 of a 10-week cycle as the RP2D.
“The primary endpoint of phase 1 was to find the recommended phase 2 dose (RP2D).”
What this piece can’t prove
  • Small phase 1 sample size (25 enrolled; 18 DLT-evaluable) limits precision in estimating DLT rates and tolerability.
  • Single-arm, non-randomised dose-finding design without a concurrent comparator arm.
  • Abstract does not report detailed DLT event types or counts for the phase 1 cohort in the text provided.
  • Phase 1 allowed up to one prior therapy in some patients, introducing heterogeneity in prior treatment exposure.
3human in vivoDescribe overall safety/tolerability of the regimen across treated patients (adverse events, serious adverse events, discontinuations).Pooled safety analysis (all treated patients across phase 1 and phase 2)Expand

In plain English

Pooled safety analysis of all treated patients (safety population n=59) showed grade 3–4 treatment-related adverse events with the most frequent being hypertension (20/59, 34%), alanine aminotransferase elevation (10/59, 17%), and aspartate aminotransferase elevation (7/59, 12%). Five patients (8%) discontinued for drug-related serious adverse events. No treatment-related deaths were reported.

Key findings

  • Grade 3–4 treatment-related adverse events were reported in the pooled safety population; the most common were hypertension, elevated alanine aminotransferase (ALT), and elevated aspartate aminotransferase (AST).Hypertension 20/59 (34%); ALT elevation 10/59 (17%); AST elevation 7/59 (12%)
  • Discontinuations due to drug-related serious adverse events occurred in a minority of patients.5/59 (8%) discontinued for drug-related serious adverse events
“Safety analyses included all patients who received any treatment.”
What this piece can’t prove
  • The pooled safety population is modest in size (n=59), limiting precision for less common adverse events.
  • Demographic skew in the reported population (94% White in phase 2) may limit generalizability of safety findings.
  • The abstract does not present a complete list of serious adverse events or laboratory/trend data beyond the reported common grade 3–4 events.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref · 39 candidate papers

Candidate

Inequities in access to precision oncology: shared challenges, unified blueprint

The Lancet Oncology · 2026 · Crossref

Source (opens in a new tab)

And 33 more candidates considered.